纳武单抗用于复发性和/或转移性头颈癌患者的再治疗。

Retreatment with nivolumab for patients with recurrent and/or metastatic head and neck cancer.

作者信息

Wakasugi Tetsuro, Takeuchi Shoko, Ohkubo Jun-Ichi, Suzuki Hideaki

机构信息

Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

出版信息

Acta Otolaryngol. 2022 Feb;142(2):206-212. doi: 10.1080/00016489.2022.2033317. Epub 2022 Feb 11.

DOI:10.1080/00016489.2022.2033317

PMID:35148228

Abstract

BACKGROUND

After treatment with an immune checkpoint inhibitor (ICI) is discontinued, retreatment with an ICI is a potential sequential treatment, but the clinical efficacy/safety data for this treatment of recurrent and/or metastatic head and neck cancer (R/M-HNC) are limited.

AIMS/OBJECTIVES: This study aimed to evaluate the efficacy and safety of retreatment with nivolumab in R/M HNC.

MATERIALS AND METHODS

We divided the 29 eligible R/M-HNC patients who discontinued ICI treatment at our hospital into two cohorts to analyze the clinical characteristics and the efficacy of the salvage therapy: the Niv cohort (nivolumab retreatment) and the no-Niv cohort (no nivolumab retreatment).

RESULTS

The Niv cohort's median overall survival (OS) of 17.5 months (95% confidence interval [CI]: 2.7-32.3) was significantly prolonged compared to that of the no-Niv cohort: 5.8 months (95%CI: 2.4-9.2, = .034). The Niv cohort achieved objective response rate of 16.7% and a disease control rate of 50.0%. No adverse events > grade 3 occurred in the Niv cohort.

CONCLUSION

Nivolumab retreatment is an option for sequential treatment post-immunotherapy.

摘要

背景

在停用免疫检查点抑制剂（ICI）治疗后，再次使用ICI进行治疗是一种潜在的序贯治疗方法，但针对复发性和/或转移性头颈癌（R/M-HNC）的这种治疗的临床疗效/安全性数据有限。

目的

本研究旨在评估纳武利尤单抗再次治疗R/M-HNC的疗效和安全性。

材料与方法

我们将在我院停用ICI治疗的29例符合条件的R/M-HNC患者分为两个队列，以分析临床特征和挽救治疗的疗效：纳武利尤单抗队列（纳武利尤单抗再次治疗）和非纳武利尤单抗队列（未进行纳武利尤单抗再次治疗）。

结果

纳武利尤单抗队列的中位总生存期（OS）为17.5个月（95%置信区间[CI]：2.7-32.3），与非纳武利尤单抗队列相比显著延长：5.8个月（95%CI：2.4-9.2，P = 0.034）。纳武利尤单抗队列的客观缓解率为16.7%，疾病控制率为50.0%。纳武利尤单抗队列未发生3级以上不良事件。